Medical Cannabis for Migraines: Which Delivery Form Fits Which Attack
A practical guide to medical cannabis for migraines: which delivery forms suit which attacks, how to dose, and where the evidence is thin.
Migraine affects about 39 million people in the United States. Evidence that cannabis treats migraine is thin. No large placebo-controlled trial has tested THC or CBD for migraine. Small studies report fewer migraine days in some users. The American Headache Society does not recommend cannabis for migraine. Ask a headache specialist first.
A 2016 chart review in the journal Pharmacotherapy tracked 121 adults with chronic migraine at a Colorado neurology clinic. Mean monthly migraine days fell from 10.4 to 4.6. The study had no control group, so placebo response is possible.
A 2020 patient survey in Cannabis and Cannabinoid Research found cannabis cut self-reported migraine pain by about half. Effects differed by product, dose, and person. Surveys rely on memory and self-report.
Cannabis for Migraines vs Triptans: Which Works First?
Both studies are small. Neither proves cause and effect.
THC binds CB1 receptors in the brain and spinal cord. That binding can change how the trigeminal nerve signals pain. CBD binds CB1 with low affinity and may slow the breakdown of anandamide, a natural endocannabinoid.
Migraine involves calcitonin gene-related peptide (CGRP). Drugs that block CGRP, such as erenumab and rimegepant, hold FDA approval for migraine. Cannabis does not.
During a migraine attack, nausea can make oral products hard to keep down. Inhaled products act faster for that reason.
Start low. Common starting points in patient reports:
THC tolerance builds with daily use. More THC does not mean better migraine control.
As of 2024, 38 states and the District of Columbia allow medical cannabis. 24 states allow adult use. Cannabis stays Schedule I under federal law. Rules differ by state and by county.